MedTrace Logo

T2 Biomarkers Predictive Value in Occupational Asthma After Cessation of Exposure.

NCT07006285 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-06-05

No results posted yet for this study

Summary

Occupational exposure is known to cause 15% of asthma cases. The main treatment for occupational asthma is to stop exposure if possible. Although, remission of occupational asthma only occurs in only 30 % of patients after cessation of exposure. There is currently no way of predicting which patients will go into remission after cessation of exposure.

In non-occupational asthma, the inflammatory biomarker T2 has allowed the entry into personalized medicine and can predict future exacerbations.

The investigators hypothesize that T2 biomarkers could be predictive markers for remission in occupational asthma after exposure cessation.

The investigators intend to carry out a follow-up study at the University Hospital of Strasbourg to perform the non-specific bronchial hyperresponsiveness test to assess remission in patients diagnosed with occupational asthma and to compare baseline T2 biomarkers in remission and non remission patients.

Conditions

  • Asthma
  • Occupational Asthma
  • Occupational Diseases

Interventions

OTHER

Measure of T2 biomarkers

T2 Biomarkers are estimated via induced sputum: Sputum is induced through increasing concentrations from 0.9 or 3% to 4% and 5% of hypertonic solution. Assessment of nonspecific bronchial hyperresponsiveness is realized by metacholine challenge

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-30
Primary Completion
2025-06-30
Completion
2026-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07006285 on ClinicalTrials.gov